Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3978)
All Articles published online
|
Feb 12, 2013 (publication date) through Dec 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Virology
ISSN
2220-3249
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Salvatierra K, Fareleski S, Forcada A, López-Labrador FX. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol 2013; 2(1): 6-15 [PMID: 24175225 DOI: 10.5501/wjv.v2.i1.6] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3249/full/v2/i1/6.htm |
| Number | Citing Articles |
| 1 |
Trang H. Au, Christopher J. Destache, Renuga Vivekanandan. Hepatitis C therapy: Looking toward interferon-sparing regimens. Journal of the American Pharmacists Association 2015; 55(2): e72 doi: 10.1331/JAPhA.2015.15508
|
| 2 |
Jun Ito, Goki Suda, Yoshiya Yamamoto, Atsushi Nagasaka, Ken Furuya, Kenichi Kumagai, Hideaki Kikuchi, Takuto Miyagishima, Tomoe Kobayashi, Megumi Kimura, Kazushi Yamasaki, Machiko Umemura, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi Terashita, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection. Hepatology Research 2016; 46(13): 1294 doi: 10.1111/hepr.12685
|
| 3 |
Kejia Ding, Annie Wang, Mark A. Boerneke, Sergey M. Dibrov, Thomas Hermann. Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorganic & Medicinal Chemistry Letters 2014; 24(14): 3113 doi: 10.1016/j.bmcl.2014.05.009
|
| 4 |
Jun Itakura, Masayuki Kurosaki, Hitomi Takada, Natsuko Nakakuki, Syuya Matsuda, Kouichi Gondou, Yu Asano, Nobuhiro Hattori, Yoshie Itakura, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Takahashi, Syinya Maekawa, Nobuyuki Enomoto, Namiki Izumi. Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy. Hepatology Research 2015; 45(10) doi: 10.1111/hepr.12474
|
| 5 |
Timothy T Spear, Timothy P Riley, Gretchen E Lyons, Glenda G Callender, Jeffrey J Roszkowski, Yuan Wang, Patricia E Simms, Gina M Scurti, Kendra C Foley, David C Murray, Lance M Hellman, Rachel H McMahan, Makio Iwashima, Elizabeth Garrett-Mayer, Hugo R Rosen, Brian M Baker, Michael I Nishimura. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. Journal of Leukocyte Biology 2016; 100(3): 545 doi: 10.1189/jlb.2A1215-561R
|
| 6 |
Skender Topi, Elona Gaxhja, Ioannis Alexandros Charitos, Marica Colella, Luigi Santacroce. Hepatitis C Virus: History and Current Knowledge. Gastroenterology Insights 2024; 15(3): 676 doi: 10.3390/gastroent15030049
|
| 7 |
Ying Cao, Yi Bao, Wei Xia, Hao Wu, Feili Wei, Yu Zhang, Renwen Zhang, Xiaoyuan Xu. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients. Clinics and Research in Hepatology and Gastroenterology 2016; 40(5): 597 doi: 10.1016/j.clinre.2016.02.004
|
| 8 |
Barbara Bartolini, Marina Selleri, Anna Rosa Garbuglia, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Gianpiero D'Offizi, Maria R. Capobianchi. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study. Journal of Clinical Virology 2015; 72: 60 doi: 10.1016/j.jcv.2015.07.310
|
| 9 |
Livia Rossi, Alejandro Escobar-Gutierrez, Paula Rahal. Advanced Molecular Surveillance of Hepatitis C Virus. Viruses 2015; 7(3): 1153 doi: 10.3390/v7031153
|
| 10 |
Iram Gull, Muhammad Shahbaz Aslam, Imran Tipu, Roohi Mushtaq, Tehseen Zamir Ali, Muhammad Amin Athar. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-47074-y
|
| 11 |
Hayat Khan, Jan Paeshuyse, Sheeba Murad, Johan Neyts. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries. Antiviral Research 2016; 125: 43 doi: 10.1016/j.antiviral.2015.10.008
|
| 12 |
Karina Salvatierra, Hector Florez. Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance. F1000Research 2016; 5: 1141 doi: 10.12688/f1000research.8740.1
|
| 13 |
Leora Schiff. Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi. Clinical Therapeutics 2015; 37(5): 1092 doi: 10.1016/j.clinthera.2015.02.009
|
| 14 |
Karina Salvatierra, Hector Florez. Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance. F1000Research 2016; 5: 1141 doi: 10.12688/f1000research.8740.2
|
| 15 |
Kaku Goto, Naoya Kato. MICA SNPs and the NKG2D system in virus-induced HCC. Journal of Gastroenterology 2015; 50(3): 261 doi: 10.1007/s00535-014-1000-9
|
| 16 |
Kerstin Herzer, Angela Papadopoulos-Köhn, Anne Achterfeld, Ali Canbay, Katja Piras-Straub, Andreas Paul, Andreas Walker, Jörg Timm, Guido Gerken. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World Journal of Hepatology 2015; 7(9): 1287-1296 doi: 10.4254/wjh.v7.i9.1287
|
| 17 |
Aqsa Ikram, Ayesha Obaid, Faryal Mehwish Awan, Rumeza Hanif, Anam Naz, Rehan Zafar Paracha, Amjad Ali, Hussnain Ahmed Janjua. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Antiviral Research 2017; 137: 112 doi: 10.1016/j.antiviral.2016.10.013
|
| 18 |
Alessio Strazzulla, Chiara Costa, Vincenzo Pisani, Vincenzo De Maria, Francesca Giancotti, Sebastiano Di Salvo, Saverio Giuseppe Parisi, Monica Basso, Marzia Maria Franzetti, Nadia Marascio, Maria Carla Liberto, Giorgio Settimo Barreca, Angelo Giuseppe Lamberti, Emilia Zicca, Maria Concetta Postorino, Giovanni Matera, Alfredo Focà, Carlo Torti. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. BMC Infectious Diseases 2014; 14(S5) doi: 10.1186/1471-2334-14-S5-S3
|